Frontiers in the Management of Retinoblastoma

American Journal of Ophthalmology

Volumn 148, Issue 2, 2009, Pages 192-198

  Lin, Phoebe ^a   O'Brien, Joan M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; ETOPOSIDE; FIBRIN GLUE; HISTONE DEACETYLASE INHIBITOR; IODINE 125; MELPHALAN; NUTLIN 3; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; RETINOBLASTOMA PROTEIN; RUTHENIUM 106; TOPOTECAN; TRANSCRIPTION FACTOR E2F; VINCRISTINE; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BRACHYTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GENETICS; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CELLULITIS; CHILDHOOD CANCER; CHROMOSOME 13Q; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED DRUG RELEASE; CRYOTHERAPY; CUTANEOUS T CELL LYMPHOMA; DISEASE CLASSIFICATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ECHOGRAPHY; ENUCLEATION; EXTERNAL BEAM RADIOTHERAPY; EYE EXAMINATION; EYE MOVEMENT; FAT NECROSIS; GENE MUTATION; GENETIC ANALYSIS; GENETIC COUNSELING; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HYPERTHERMIC THERAPY; ISCHEMIC OPTIC NEUROPATHY; LASER COAGULATION; LOW DRUG DOSE; METASTASIS; MISSENSE MUTATION; MULTICENTER STUDY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPHTHALMOSCOPY; OPTIC NERVE ATROPHY; ORBIT DISEASE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PROTEIN INTERACTION; PUPIL; RETINOBLASTOMA; SALVAGE THERAPY; SIDE EFFECT; SLIT LAMP; TREATMENT OUTCOME; VISION; VISUAL ACUITY;

ANTINEOPLASTIC AGENTS; BRACHYTHERAPY; COMBINED MODALITY THERAPY; CRYOTHERAPY; EYE ENUCLEATION; HUMANS; HYPERTHERMIA, INDUCED; LASER COAGULATION; MOLECULAR BIOLOGY; MOLECULAR DIAGNOSTIC TECHNIQUES; RADIOTHERAPY, HIGH-ENERGY; RETINAL NEOPLASMS; RETINOBLASTOMA;

EID: 67650443984     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2009.04.004     Document Type: Article

References (43)

1. Abramson D.H. Retinoblastoma incidence in the United States. Arch Ophthalmol 108 (1990) 1514
2. Devesa S.S. The incidence of retinoblastoma. Am J Ophthalmol 80 (1975) 263-265
3. Leal-Leal C., Flores-Rojo M., Medina-Sanson A., et al. A multicentre report from the Mexican Retinoblastoma Group. Br J Ophthalmol 88 (2004) 1074-1077
4. Abramson D.H. Retinoblastoma in the 20th century: past success and future challenges the Weisenfeld lecture. Invest Ophthalmol Vis Sci 46 (2005) 2683-2691
5. Albert D.M. Historic review of retinoblastoma. Ophthalmology 94 (1987) 654-662
6. Dondey J.C., Staffieri S., McKenzie J., Davie G., and Elder J. Retinoblastoma in Victoria, 1976-2000: changing management trends and outcomes. Clin Experiment Ophthalmol 32 (2004) 354-359
7. Berman E.L., Donaldson C.E., Giblin M., and Martin F.J. Outcomes in retinoblastoma, 1974-2005: the Children's Hospital, Westmead. Clin Experiment Ophthalmol 35 (2007) 5-12
8. Friend S.H., Bernards R., Rogelj S., et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323 (1986) 643-646
9. Abramson D.H., and Schefler A.C. Update on retinoblastoma. Retina 24 (2004) 828-848
10. Linn Murphree A. Intraocular retinoblastoma: the case for a new group classification. Ophthalmol Clin North Am 18 (2005) 41-53 viii
11. Shields C.L., Mashayekhi A., Au A.K., et al. The International Classification of Retinoblastoma predicts chemoreduction success. Ophthalmology 113 (2006) 2276-2280
12. Chantada G., Doz F., Antoneli C.B., et al. A proposal for an International Retinoblastoma Staging System. Pediatr Blood Cancer 47 (2006) 801-805
13. Shields C.L., Honavar S.G., Meadows A.T., Shields J.A., Demirci H., and Naduvilath T.J. Chemoreduction for unilateral retinoblastoma. Arch Ophthalmol 120 (2002) 1653-1658
14. Shields C.L., Santos M.C., Diniz W., et al. Thermotherapy for retinoblastoma. Arch Ophthalmol 117 (1999) 885-893
15. Zage P.E., Reitman A.J., Seshadri R., et al. Outcomes of a two-drug chemotherapy regimen for intraocular retinoblastoma. Pediatr Blood Cancer 50 (2008) 567-572
16. Mulvihill A., Budning A., Jay V., et al. Ocular motility changes after sub-Tenon carboplatin chemotherapy for retinoblastoma. Arch Ophthalmol 121 (2003) 1120-1124
17. Kiratli H., Kocabeyoglu S., and Bilgic S. Severe pseudo-preseptal cellulitis following sub-Tenon's carboplatin injection for intraocular retinoblastoma. J AAPOS 11 (2007) 404-405
18. Schmack I., Hubbard G.B., Kang S.J., Aaberg Jr. T.M., and Grossniklaus H.E. Ischemic necrosis and atrophy of the optic nerve after periocular carboplatin injection for intraocular retinoblastoma. Am J Ophthalmol 142 (2006) 310-315
19. Shields J.A., Shields C.L., and Meadows A.T. Chemoreduction in the management of retinoblastoma. Am J Ophthalmol 140 (2005) 505-506
20. Chantada G.L., Dunkel I.J., Antoneli C.B., et al. Risk factors for extraocular relapse following enucleation after failure of chemoreduction in retinoblastoma. Pediatr Blood Cancer 49 (2007) 256-260
21. Chantada G.L., Doz F., Orjuela M., et al. World disparities in risk definition and management of retinoblastoma: a report from the International Retinoblastoma Staging Working Group. Pediatr Blood Cancer 50 (2008) 692-694
22. Roarty J.D., McLean I.W., and Zimmerman L.E. Incidence of second neoplasms in patients with bilateral retinoblastoma. Ophthalmology 95 (1988) 1583-1587
23. Marees T., Moll A.C., Imhof S.M., de Boer M.R., Ringens P.J., and van Leeuwen F.E. Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. J Natl Cancer Inst 100 (2008) 1771-1779
24. Dunkel I.J., Aledo A., Kernan N.A., et al. Successful treatment of metastatic retinoblastoma. Cancer 89 (2000) 2117-2121
25. Rodriguez-Galindo C., Wilson M.W., Haik B.G., et al. Treatment of metastatic retinoblastoma. Ophthalmology 110 (2003) 1237-1240
26. Kremens B., Wieland R., Reinhard H., et al. High-dose chemotherapy with autologous stem cell rescue in children with retinoblastoma. Bone Marrow Transplant 31 (2003) 281-284
27. Valverde J.R., Alonso J., Palacios I., and Pestana A. RB1 gene mutation update, a meta-analysis based on 932 reported mutations available in a searchable database. BMC Genet 6 (2005) 53
28. Leiderman Y.I., Kiss S., and Mukai S. Molecular genetics of RB1- the retinoblastoma gene. Semin Ophthalmol 22 (2007) 247-254
29. Lohmann D.R., and Gallie B.L. Retinoblastoma: revisiting the model prototype of inherited cancer. Am J Med Genet C Semin Med Genet 129C (2004) 23-28
30. Klutz M., Brockmann D., and Lohmann D.R. A parent-of-origin effect in two families with retinoblastoma is associated with a distinct splice mutation in the RB1 gene. Am J Hum Genet 71 (2002) 174-179
31. MacPherson D., Conkrite K., Tam M., Mukai S., Mu D., and Jacks T. Murine bilateral retinoblastoma exhibiting rapid-onset, metastatic progression and N-myc gene amplification. Embo J 26 (2007) 784-794
32. Honda R., Tanaka H., and Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420 (1997) 25-27
33. Laurie N.A., Donovan S.L., Shih C.S., et al. Inactivation of the p53 pathway in retinoblastoma. Nature 444 (2006) 61-66
34. Elison J.R., Cobrinik D., Claros N., Abramson D.H., and Lee T.C. Small molecule inhibition of HDM2 leads to p53-mediated cell death in retinoblastoma cells. Arch Ophthalmol 124 (2006) 1269-1275
35. Rosato R.R., Almenara J.A., and Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 63 (2003) 3637-3645
36. Dalgard C.L., van Quill K.R., and O'Brien J.M. Evaluation of the in vitro and in vivo anti-tumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma. Clin Cancer Res 14 (2008) 3113-3123
37. Tonelli R., Purgato S., Camerin C., et al. Anti-gene peptide nucleic acid specifically inhibits MYCN expression in human neuroblastoma cells leading to cell growth inhibition and apoptosis. Mol Cancer Ther 4 (2005) 779-786
38. MacPherson D., and Dyer M.A. Retinoblastoma: from the two-hit hypothesis to targeted chemotherapy. Cancer Res 67 (2007) 7547-7550
39. Van Quill K.R., Dioguardi P.K., Tong C.T., et al. Subconjunctival carboplatin in fibrin sealant in the treatment of transgenic murine retinoblastoma. Ophthalmology 112 (2005) 1151-1158
40. Tsui J.Y., Dalgard C., van Quill K.R., et al. Subconjunctival topotecan in fibrin sealant in the treatment of transgenic murine retinoblastoma. Invest Ophthalmol Vis Sci 49 (2008) 490-496
41. Suzuki S., and Kaneko A. Management of intraocular retinoblastoma and ocular prognosis. Int J Clin Oncol 9 (2004) 1-6
42. Yamane T., Kaneko A., and Mohri M. The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma. Int J Clin Oncol 9 (2004) 69-73
43. Abramson D.H., Dunkel I.J., Brodie S.E., Kim J.W., and Gobin Y.P. A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology 115 (2008) 1398-1404